Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/41726
Title: Protective role of Edaravone against valproic acid induced changes in skin
Authors: Tunali-Akbay, Tugba
Alev, Burcin
Tunali, Sevim
Oktay, Sehkar
Emekli-Alturfan, Ebru
Ipekci, Hazal
Ozturk, Leyla Koc
Yanardag, Refiye
Yarat, Aysen
Keywords: Adverse drug reaction;Antiepileptic drug;Oxidative damage;Scavenger;Side effects;Tissue Factor Activity
Issue Date: May-2017
Publisher: NISCAIR-CSIR, India
Abstract: Valproic acid (VPA) is an antiepileptic drug known to have some adverse effects on gastrointestinal, neurologic, hematologic and reproductive systems. In this study, we investigated the effect of edaravone (3-methyl-1-phenyl-2-pyrazoline-5-one), a potent free radical scavenger, on skin oxidative and inflammatory changes caused by VPA. Female rats were randomly divided into four groups: control, edaravone (30 mg/kg/day, i.p.), VPA (0.5 g/kg/day, i.p.), and VPA+edaravone (in same dose, i.p.). On the 8th day of experiment, all the animals were fasted overnight and then sacrificed under anesthesia. Malondialdehyde, glutathione, total sialic acid and total protein levels, superoxide dismutase, glutathione-S-transferase, catalase, glutathione peroxidase, Na+/K+-ATPase, myeloperoxidase and tissue factor activities were determined in homogenized skin samples. VPA administration significantly altered the skin oxidant and antioxidant balance which may cause skin cell damage. Edaravone, as an antioxidant, demonstrated its radical scavenger effect, especially on malondialdehyde level and glutathione-S-transferase activity. Edaravone, by preventing inflammatory and oxidative reactions, partly protected the skin against the changes observed after the VPA administration.
Page(s): 286-291
ISSN: 0975-1009 (Online); 0019-5189 (Print)
Appears in Collections:IJEB Vol.55(05) [May 2017]

Files in This Item:
File Description SizeFormat 
IJEB 55(5) 286-291.pdf178.02 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.